Jefferies keeps SFBC at buy

SFBC International Inc. was maintained by Jefferies & Co., Inc. analyst David Windley at a buy. The analyst is optimistic about the company into 2007 with its book-to-bill of 1.56 and 9% sequential backlog growth for PharmaNet. SFBC reported total revenue of $72.8 million, slightly lower than Jefferies' published $74 million. Shares of the Princeton, N.J.-based drug development services company were down 53 cents, or 3.11%, at $16.51, on volume of 358,732 shares versus the three-month running average of 509,159 shares. (Nasdaq: SFCC)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.